NCT06781567View on ClinicalTrials.gov

Clinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

December 13, 2024

Primary Completion Date

December 31, 2028

Study Completion Date

June 30, 2029

Conditions
Adenoid Cystic CarcinomaHead and Neck Cancer
Interventions
DRUG

HG146

HG146 is available as Capsule at a unit dose strength of 5 mg and 10 mg.

Trial Locations (1)

200000

RECRUITING

Shanghai Oriental Hospital, Shanghai

Sponsors

Lead Sponsor

HitGen Inc.
All Listed Sponsors
lead

HitGen Inc.

INDUSTRY